Abstracts tagged "Autoinflammatory Disease"

Abstract Number: 2863 • 2018 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety of Canakinumab in Patients with Colchicine-Resistant FMF (crFMF), Hids/Mkd and TRAPS: Results from the Pivotal Phase 3 Cluster Trial
Fabrizio De Benedetti¹, Joost Frenkel², Anna Simon³, Jordi Anton⁴, Helen J. Lachmann⁵, Marco Gattorno⁶, Seza Ozen⁷, Isabelle Koné-Paut⁸, Eldad Ben-Chetrit⁹, Magdalena Wozniak¹⁰, Xiaoling Wei¹¹ and Eleni Vritzali¹², ¹IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ²University Medical Center,Utrecht, Utrecht, Netherlands, ³General Internal Medicine, Radboud University, Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Unitat de Reumatologia Pediàtrica, Hospital Sant Joan de Déu, Barcelona, Spain, ⁵UCL Division of Medicine, UK National Amyloidosis Centre, London, United Kingdom, ⁶Pediatric Division, G Gaslini Institute, Genoa, Italy, ⁷Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁸APHP, CHU de Bicêtre, University of Paris SUD, Paris, France, ⁹Rheumatology Unit, Hadassah—Hebrew University Medical Center, Jerusalem, Israel, ¹⁰Novartis Ireland Ltd, Dublin, Ireland, ¹¹China Novartis Institutes for Biomedical Research Co., Ltd, Beijing, China, ¹²Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Canakinumab (CAN), a selective, human anti-interleukin (IL)-1β has demonstrated efficacy and safety in patients (pts) with colchicine-resistant familial Mediterranean fever (crFMF), hyper-IgD syndrome (HIDS)/mevalonate…
Abstract Number: 169 • 2017 ACR/ARHP Annual Meeting
New Autoinflammatory Phenotype Associated with Homozygous AGBL3 Variant
Ahmet Gül¹, Neslihan Abaci² and Sema Sirma Ekmekci², ¹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Department of Genetics, Istanbul University Institute for Experimental Medical Research, Istanbul, Turkey
Background/Purpose: To identify new genes/pathways associated with autoinflammatory phenotype. Methods: We screened genomic variations by whole exome sequencing in 3 families presented with autoinflammatory findings…
Abstract Number: 290 • 2017 ACR/ARHP Annual Meeting
Characterization of Neutrophil Subsets and Neutrophil Extracellular Traps in Pyogenic Arthritis, Pyoderma Gangrenosum and Acne (PAPA) Syndrome
Pragnesh Mistry¹, Carmelo Carmona-Rivera¹, Nickie Seto¹, Monica Purmalek¹, Amanda Ombrello², Ivona Aksentijevich², Daniel L. Kastner² and Mariana J. Kaplan¹, ¹Systemic Autoimmunity Branch, NIAMS/NIH, Bethesda, MD, ²Inflammatory Disease Section, NHGRI/NIH, Bethesda, MD
Background/Purpose: Pyogenic arthritis, pyoderma gangrenosum and acne (PAPA) syndrome is an autosomal dominant autoinflammatory disorder caused by mutations in the PSTPIP1/CD2BP1 gene. PAPA syndrome is…
Abstract Number: 361 • 2017 ACR/ARHP Annual Meeting
Multi-National Observational Patient Diary Study to Assess Disease Burden of Periodic Fever Syndromes (PFS), Including Colchicine-Resistant Familial Mediterranean Fever (crFMF), TNF-Receptor Associated Periodic Syndrome (TRAPS) and Mevalonate Kinase Deficiency (MKD)
Jasmin B. Kuemmerle-Deschner¹, Pierre Quartier², Shai Padeh³, Isabelle Koné-Paut⁴, Veronique Hentgen⁵, Katherine A. Marzan⁶, Fatma Dedeoglu⁷, Helen J. Lachmann⁸, Tilmann Kallinich⁹, Norbert Blank¹⁰, Seza Ozen¹¹, Yelda Bilginer¹², Jonathan S. Hausmann^7,13, Arturo Diaz¹³, Ravi Degun¹⁴, Nina Marinsek¹⁴, Jill Gregson¹⁵, Kathleen G. Lomax¹⁶ and Avi Livneh¹⁷, ¹Pediatrics, University Hospital Tübingen, Tübingen, Germany, ²Necker-Enfants Malades Hospital, Paris, France, ³Sheba Medical Center, Tel-Hashomer, Israel, ⁴Bicêtre Hospital, APHP, Univeristy Paris Sud, Paris, France, ⁵Versailles Hospital, CEREMAI, Le Chesnay, France, ⁶Division of Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, ⁷Boston Children's Hospital, Boston, MA, ⁸UCL Division of Medicine, UK National Amyloidosis Centre, London, United Kingdom, ⁹Charité, Humbolt University Medicine Berlin, Berlin, Germany, ¹⁰UniversitätsKlinikum Heidelberg, Heidelberg, Germany, ¹¹Department of Pediatrics, Hacettepe University, Ankara, Turkey, ¹²Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, ANKARA, Turkey, ¹³Beth Israel Deaconess Medical Center, Boston, MA, ¹⁴Life Sciences, Navigant Consulting, London, United Kingdom, ¹⁵Novartis Pharma AG, Basel, Switzerland, ¹⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁷Sheba Medical Center, Ramat-Gan, Israel
Background/Purpose: Periodic fever syndromes (PFS) are a group of autoinflammatory disorders characterized by recurrent bouts of fever and severe localized inflammation which, if not treated,…
Abstract Number: 367 • 2017 ACR/ARHP Annual Meeting
Interleukin-1 Receptor Antagonist Is a Potential Treatment for Undifferentiated Autoinflammatory Syndromes
Ananta Subedi¹, Daniella Schwartz², Karyl Barron³, Daniel L. Kastner⁴ and Amanda Ombrello⁵, ¹National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, ²NIAMS - Rheumatology, National Institutes of Health, Bethesda, MD, ³National Institutes of Health, Inflammatory Disease Section, National Human Genome Research Institute, Bethesda, MD, ⁴Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ⁵Inflammatory Disease Section, NHGRI/NIH, Bethesda, MD
Background/Purpose: The autoinflammatory diseases (AIDs) are a group of disorders of the innate immune system characterized by seemingly unprovoked inflammation1. A variety of genetic alterations…
Abstract Number: 379 • 2017 ACR/ARHP Annual Meeting
H Syndrome: Five New Cases from the United States with Novel Features and Responses to Therapy
Jessica Bloom¹, Clara Lin², Lisa F. Imundo³, Stephen Guthery⁴, Shelly Stepenaskie⁵, Csaba Galambos⁶, Amy Lowichik⁷ and John F. Bohnsack⁸, ¹Pediatrics, Children's Hospital Colorado, Aurora, CO, ²Pediatric Rheumatology, Children's Hospital Colorado, Aurora, CO, ³Pediatrics, Columbia University Medical Center, New York, NY, ⁴Department of Pediatrics,, University of Utah, Salt Lake City, UT, ⁵Pathology and Dermatology, University of New Mexico, Albuquerque, NM, ⁶Pathology, Children's Hospital Colorado, Aurora, CO, ⁷Pathology, University of Utah, Salt Lake City, UT, ⁸Division of Allergy, Immunology and Pediatric Rheumatology, University of Utah, Salt Lake City, UT
Background/Purpose: H Syndrome is an autosomal recessive disorder characterized by cutaneous hyperpigmentation, hypertrichosis, and induration with numerous systemic manifestations. The syndrome is caused by mutations…
Abstract Number: 942 • 2017 ACR/ARHP Annual Meeting
Role of the Pyrin Inflammasome in Resistance to Yersinia Pestis: A Possible Selective Advantage for Carriers of MEFV Mutations
Yong Hwan Park¹, Wonyong Lee¹, Lawton Chung², James Bliska², Daniel L. Kastner¹ and Jae Jin Chae³, ¹Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ²Department of Molecular Genetics and Microbiology, School of Medicine, Stony Brook University, Stony Brook, NY, ³Inflammatory disease section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: Mutations in MEFV, encoding pyrin, cause the prototypic autoinflammatory disease, familial Mediterranean fever (FMF). The carrier frequency of FMF-associated MEFV mutations is extraordinarily high…
Abstract Number: 1027 • 2017 ACR/ARHP Annual Meeting
Quantification of Leukocytes’ Secretome to Guide Diagnosis and Treatment Options in Patients with Suspected Chronic Auto-Inflammatory Syndromes
Philippe A. Tessier¹, Marie-Pier Longchamps¹, Nathalie Amiable¹, Nathalie Pagé¹, Laetitia Michou², Louis Bessette², Paul R. Fortin¹, Alexandra Albert², Anne-Laure Chetaille² and Martin Pelletier¹, ¹Infectious Diseases and Immunity Research Division, CHU de Québec-Université Laval Research Center, Québec, QC, Canada, ²Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Québec, QC, Canada
Background/Purpose: Auto-inflammatory syndromes are inherited conditions characterized by recurrent inflammation (fever, abdominal pain, dermatitis, arthritis). Diagnosis and treatments are challenging as detection rate of mutations…
Abstract Number: 1154 • 2017 ACR/ARHP Annual Meeting
Use of Including Serum Ferritin and Heme Oxygenase 1 in the Yamaguchi’s Classification for Adult-Onset Still’s Disease: A Multicenter Retrospective Study
Yohei Kirino¹, Yasushi Kawaguchi², Yoshifumi Tada³, Hiroshi Tsukamoto⁴, Toshiyuki Ota⁵, Masahiro Iwamoto⁶, Hiroki Takahashi⁷, Kohei Nagasawa⁸, Syuji Takei⁹, Takahiko Horiuchi¹⁰, Hisae Ichida², Seiji Minota¹¹, Atsuhisa Ueda¹, Akihide Ohta¹² and Yoshiaki Ishigatsubo¹³, ¹Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ³Department of Internal Medicine, Division of Rheumatology, Saga University, Saga, Japan, ⁴Department of medicine and biosystemic science, Kyushu University Hospital, Fukuoka, Japan, ⁵Department of Rheumatology, Iizuka Hospital, Iizuka, Japan, ⁶Deivision of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke, Japan, ⁷Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan, ⁸Rheumatic Disease Center, Sawara Hospital, Sawara, Japan, ⁹Pediatrics of Developmental Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan, ¹⁰Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, ¹¹Department of Internal Medicine, Division of Rheumatology/Clinical Immunology, Jichi Medical University, Shimotsuke, Japan, ¹²Saga University School of Medicine, Saga, Japan, ¹³Yokohama City University, Yokohama, Japan
Background/Purpose: Yamaguchi’s criteria for classification of adult-onset Still’s disease (AOSD) has been widely applied in clinic despite it was established decades ago. However, hyperferritinemia, which…
Abstract Number: 1892 • 2017 ACR/ARHP Annual Meeting
A20 Haploinsufficiency: Clinical Phenotypes and Disease Course of Patients with This Newly Recognized Autoinflammatory Disease
Florence A. Aeschlimann¹, Ezgi Deniz Batu², Ellen Go³, Ahmet Gül⁴, Patrycja M. Hoffmann⁵, Helen L. Leavis⁶, Seza Ozen⁷, Annet van Royen-Kerkof⁶, Daniella Schwartz⁸, Deborah L. Stone⁹, Ivona Aksentijevich¹⁰, Daniel L. Kastner¹¹ and Ronald Laxer¹, ¹Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ²Pediatric Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Pediatrics, Indiana University School of Medicine, Indianapolis, IN, ⁴Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ⁵Inflammatory Disease Section, National Human Genome Research Institute, Bethesda, MD, ⁶Pediatric Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁷Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁸NIAMS - Rheumatology, National Institutes of Health, Bethesda, MD, ⁹Inflammatory Disease Section, NHGRI/NIH, Bethesda, MD, ¹⁰National Human Genome Research Institute, National Institutes of Health, Inflammatory Disease Section, Bethesda, MD, ¹¹Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: Haploinsufficiency of A20 (HA20) is a newly discovered autoinflammatory disease caused by mutations in TNFAIP3. A20 is a protein with a crucial role in…
Abstract Number: 1893 • 2017 ACR/ARHP Annual Meeting
Pharmacokinetics (PK), Pharmacodynamics (PD), and Proposed Dosing of Oral Janus Kinase (JAK)1 and JAK2 Inhibitor Baricitinib in Patients with IFN-Mediated Autoinflammatory Diseases (AIDs)
Hanna Kim¹, Kristina M. Brooks², Paul Wakim³, Mary Blake⁴, Stephen R. Brooks⁵, Gina A. Montealegre Sanchez⁶, Adriana Almeida de Jesus⁶, Yan Huang⁶, Wanxia Li Tsai⁷, Massimo G. Gadina⁴, Parag Kumar² and Raphaela Goldbach-Mansky⁶, ¹Pediatric Translational Research Branch, NIAMS/NIH, Bethesda, MD, ²Clinical Pharmacokinetics Research Unit, Pharmacy Department, NIH Clinical Center, Bethesda, MD, ³Biostatistics and Clinical Epidemiology Service, NIH Clinical Center, Bethesda, MD, ⁴Translational Immunology Section, Office of Science and Technology, NIAMS/NIH, Bethesda, MD, ⁵Biodata Mining and Discovery Section, Office of Science and Technology, NIAMS/NIH, Bethesda, MD, ⁶Translational Autoinflammatory Disease Studies (TADS), Laboratory of Clinical Investigation and Microbiology (LCIM), NIAID/NIH, Bethesda, MD, ⁷Translational Immunology, Office of Science and Technology, NIAMS/NIH, Bethesda, MD
Background/Purpose: JAK inhibitors reduce IFN-signaling ex vivo. We evaluated the PK and PD of the oral JAK1 and JAK2 inhibitor, baricitinib, from data collected in…
Abstract Number: 2349 • 2017 ACR/ARHP Annual Meeting
Interferon Signature in Childhood Rheumatic Diseases
Hafize Emine Sonmez¹, İ. Çağatay Karaaslan², Ezgi Deniz Batu³, Banu Anlar⁴, Betul Sozeri⁵, Adriana Almeida de Jesus⁶, Raphaela Goldbach-Mansky⁷ and Seza Ozen⁸, ¹Department of Pediatrics, Divison of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Department of Molecular Biology, Hacettepe University, Ankara, Turkey, ³Pediatric Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁴Department of Pediatrics, Division of Neurology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁵Pediatric Rheumatology, Ümraniye Tranning and Research Hospital, İstanbul, Turkey, ⁶National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, ⁷Translational Autoinflammatory Disease Studies (TADS), Laboratory of Clinical Investigation and Microbiology (LCIM), NIAID/NIH, Bethesda, MD, ⁸Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Background/Purpose: Several rheumatic diseases are characterized by overexpression of type I interferon(IFN)-inducible or viral response genes, termed the IFN signature. Recently this signature has been…
Abstract Number: 2758 • 2017 ACR/ARHP Annual Meeting
Response to JAK1/2 Inhibition with Baricitinib in “Candle”, “Savi” and “Candle-like” Diseases. a New Therapeutic Approach for Type I IFN-Mediated Autoinflammatory Diseases
Gina A. Montealegre Sanchez¹, Adam Reinhardt², Suzanne Ramsey³, Helmut Wittkowski⁴, Philip J Hashkes⁵, Sara Murias⁶, Yackov Berkun⁷, Susanne Schalm⁸, Jason A Dare⁹, Diane Brown¹⁰, Deborah L. Stone¹¹, Ling Gao⁹, Thomas L. Klausmeier¹², John D. Carter¹³, Robert Colbert¹⁴, Dawn C. Chapelle¹⁵, Hanna Kim¹⁵, Samantha Dill¹⁵, Adriana Almeida de Jesus¹, Paul Wakim¹⁶, A. Zlotogorski¹⁷, Seza Ozen¹⁸, Paul Brogan¹⁹ and Raphaela Goldbach-Mansky¹, ¹Translational Autoinflammatory Disease Studies (TADS), Laboratory of Clinical Investigation and Microbiology (LCIM), NIAID/NIH, Bethesda, MD, ²Faculty of Physicians of the University of Nebraska Medical Center, College of Medicine, Nebraska, NE, ³Pediatric Rheumatology, IWK Health Centre, Dalhousie University, Halifax, NS, Canada, ⁴Department of Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany, ⁵Pediatrics Rheumatology; Shaare Zedek Medical Center, Jerusalem, Israel, ⁶Hospital Infantil La Paz, Madrid, Spain, ⁷Hadassah-Hebrew University Medical Center, Jerusalem, Israel, ⁸Hauner Children's Hospital LMU, Munich, Germany, ⁹University of Arkansas for Medical Sciences, Little Rock, AR, ¹⁰Division Of Rheumatology MS #60, Children's Hospital Los Angeles, Los Angeles, CA, ¹¹NHGRI/NIH, Bethesda, MD, ¹²Riley Hospital for Children, Indianapolis, IN, ¹³Division of Rheumatology, University of South Florida, Tampa, FL, ¹⁴NIAMS/NIH, Bethesda, MD, ¹⁵Pediatric Translational Research Branch, NIAMS/NIH, Bethesda, MD, ¹⁶Biostatistics and Clinical Epidemiology Service, NIH Clinical Center, Bethesda, MD, ¹⁷Department of Dermatology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, ¹⁸Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ¹⁹UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom
Background/Purpose: Monogenic autoinflammatory interferonopathies, including chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures (CANDLE) and STING-associated vasculopathy with onset in infancy (SAVI), present with…
Abstract Number: 2773 • 2017 ACR/ARHP Annual Meeting
Severe Juvenile Arthritis Associated with a De Novo Gain-of-Function Germline Mutation in MYD88
Keith A. Sikora¹, Joshua R. Bennett², Laurens Vyncke³, Zuoming Deng⁴, Wanxia Li Tsai², Ewald Pauwels⁵, Gerlinde Layh-Schmitt², April D. Brundidge², Fatemeh Navid², Kristien Zaal⁶, Eric Hanson², Massimo G. Gadina⁷, Louis M. Staudt⁸, Thomas A. Griffin⁹, Jan Tavernier³, Frank Peelman³ and Robert Colbert², ¹Pediatric Translational Research Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Department of Biochemistry, Ghent University, Ghent, Belgium, ⁴Biodata Mining & Discovery, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁵Center for Molecular Modeling, Ghent University, Ghent, Belgium, ⁶Light Imaging Section, Office of Science and Technology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁷Translational Immunology, Office of Science and Technology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁸National Cancer Institute, National Institutes of Health, Bethesda, MD, ⁹Levine Children’s Hospital at Carolinas Medical Center, Charlotte, NC
Background/Purpose: Using whole exome sequencing, we discovered a de novo heterozygous germline mutation in MYD88 (myeloid differentiation primary response 88) (c.666T>G, p.S222R) in a child…
Abstract Number: 31 • 2017 Pediatric Rheumatology Symposium
Predicting therapy response to IL-1 blockade in systemic JIA: a biomarker search
Nienke M. ter Haar¹, Rianne C. Scholman¹, Wilco de Jager², Nadia Ryter³, Ariane de Ganck⁴, Dirk Foell⁵, Sytze de Roock⁶ and Bas Vastert⁷, ¹Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Dept Immunology, UMC Utrecht, Utrecht, Netherlands, ³BÜHLMANN Laboratories AG, Basel, Switzerland, ⁴Biogazelle NV, Zwijnaarde, Belgium, ⁵Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany, ⁶Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁷Division of Pediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Systemic onset juvenile idiopathic arthritis (sJIA) is an autoinflammatory disease, characterized by fever, rash and arthritis. The IL-1 and IL-6 pathway are crucial in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].